July 23, 2013 – “Mendel Biotechnology, Inc., and Fundación MEDINA have entered into a license collaboration that will enable Mendel to identify novel biostimulant products….”
Natural Products News
Bill Fenical’s group has reported discovery of a novel marine bacterial product, anthracimycin, active against Bacillus anthracis and methicillin-resistant Staphylococcus aureus (Angew. Chem. Int. Ed. 2013, doi: 10.1002/anie.201302749, published online 17 June 2013). This compound, derived from marine bacteria, may represent a new class of antibacterial compounds. (Highlighted: C&ENews, 1 July 2013, p 19; Angew. Chem. [...]
United States Pharmacopeial Convention announced Monday the availability of a new compendium that “offers freely available testing standards to help ensure the quality of herbal ingredients used in traditional medicines”
“Biosortia Pharmaceuticals Creating [Anti-Cancer] Drug Discovery Opportunity with Previously Unstudied Microorganisms”May 4th, 2013
Douglas Kinghorn (PI, Ohio State University College of Pharmacy) and colleagues will work closely with Guy Carter (Biosortia Chief Scientific Officer) to discover new, active compounds with activity toward human colon and other cancers from pre-fractionated extracts from microorganism corsortia.
The SciFinder Science in the News series has posted three videos (Feb 22 to Mar 21) on YouTube highlighting “ever-evolving and important world of” natural products chemistry. Featured in the videos are Doug Kinghorn, Gordon Cragg and Roger Schenck. Part 1 can be viewed at http://www.youtube.com/watch?v=VyxaVbtBZ9Q, Part 2 at http://www.youtube.com/watch?v=dG9Cn_WYexk, and Part 3 at http://www.youtube.com/watch?v=IdwQBpC9fm4.
Bradley S. Moore (ASP Vice-President) has been named as a 2013 receipient of the American Chemical Society Arthur C. Cope Scholar Award (C&E News, Mar 4, p 60). The award is bestowed to recognize outstanding achievement in organic chemistry. Bradley’s award is in recognition of his efforts to understand the biosynthesis of complex marine nature [...]
“On New Year’s Eve of 2012, the US Food and Drug Administration (FDA) announced its approval of crofelemer (Fulyzaq™, Salix Pharmaceuticals, Ltd., Raleigh, North Carolina) — marking the second time a botanical, and the first time an orally administered botanical, has received drug approval…”
Cooperative agreement will focus on anticancer drug development from Malaysian tree.
PharmaMar advances ecteinascidin drug PM01183 to Phase II for refractory ovarian, lung, breast cancersNovember 5th, 2012